AIM ImmunoTech proposes cGMP manufacturing for Polynucleotide drug substances
AIM ImmunoTech has submitted a proposal to Sterling Pharma Solutions for the cGMP manufacture of PolyI and Poly C12U drug substance batches. This submission outlines a detailed project plan for the scale-up and manufacturing of polynucleotides in aqueous frozen solution at Sterling's Dudley site.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day